These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26174889)

  • 1. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
    Shebl A; Gabriel S; Van Dinther K; Hubsch A; Lawo JP; Hoefferer L; Welsh S
    Transfusion; 2020 Jun; 60(6):1278-1286. PubMed ID: 32410287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
    Siani B; Willimann K; Wymann S; Marques AA; Widmer E
    Biol Ther; 2014 Dec; 4(1-2):15-26. PubMed ID: 24841428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
    Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
    Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.
    Bürzle M; Hubsch A; Spiegl N; Roten T; Marques A; Martig L; Shebl A; Stadler D
    Anal Biochem; 2020 Feb; 591():113534. PubMed ID: 31821802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contamination of IgG preparation for intravenous use with IgA. II. Removal of IgA1 from IgG preparation using affinity chomatography on lectin jacalin columns].
    Dovezenski N; Velicković Z; Tosić Lj; Nikolić G; Popović O; Romić M; Djokić M; Mijusković Z
    Srp Arh Celok Lek; 1994; 122 Suppl 1():51-2. PubMed ID: 18173187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
    Duellberg C; Hannappel A; Kistner S; Maneg O
    Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline.
    Cramer M; Frei R; Sebald A; Mazzoletti P; Maeder W
    Vox Sang; 2009 Apr; 96(3):219-25. PubMed ID: 19207169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations.
    Maranich AM; Rajnik M
    Pediatrics; 2009 Sep; 124(3):e484-8. PubMed ID: 19706589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimized microplate-based method to evaluate complement-dependent hemolysis mediated by intravenous immunoglobulins (IVIG).
    Wang Y; Khalenkov A; Scott DE
    Biologicals; 2022 Jul; 78():1-9. PubMed ID: 35842374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.